Wellage Real Hyaluronic Blue 100 Ampoule Is Quietly Taking Over US Shelves

Wellage — the clinical skincare brand under Korean biotech company Hugel — won the essence and serum category at last year's Olive Young Awards. That win wasn't just a trophy moment: it became the launchpad for one of the more quietly aggressive K-beauty retail expansions happening right now.

The product at the center of it all is the Real Hyaluronic Blue 100 Ampoule, which built its domestic credibility through Olive Young before Hugel started using that same retail relationship to push into the US market. The logic is clean — prove it at home, then leverage the Olive Young name abroad.

Here's where it gets interesting for anyone tracking K-beauty's physical retail footprint in the US. Wellage entered the California Olive Young Pasadena location in May this year, expanded to the Century City location in June, and then — in August — landed inside Sephora US as part of Olive Young's K-Beauty Edit collaboration with Sephora. That last move put Wellage products into over 580 Sephora stores across the US plus Sephora's online store.

The nine products supplied to US Olive Young locations span the Real Hyaluronic line alongside Cica and PDRN product types. So it's not just the ampoule — the brand is building a multi-line presence rather than riding a single hero product.

On the distribution side, Wellage was already on Amazon US and Canadian Costco before the Sephora deal landed. The Sephora placement specifically matters because it shifts the brand from online-only discovery to the kind of in-store browsing that converts new customers who've never heard of Hugel or Wellage before.

The overseas revenue numbers back this up: in the first four months of this year alone, Wellage's international sales were up roughly 95% versus the same period last year, with the brand present in 12 countries at that point.

For context on why Hugel is pushing this hard: their cosmetics division — which Wellage drives — grew from 422 billion won in 2024 to 616 billion won last year, a jump of nearly 46%. Through the first three quarters of this year, the division has already hit 584 billion won, which is about 95% of all of last year's cosmetics revenue in just nine months. Meanwhile, their core botulinum toxin business saw a 21% revenue decline in Q3 — so the cosmetics push isn't just a side project anymore, it's actively compensating for softness in the legacy business.

If you're stateside and curious about the ampoule that started all of this, the Sephora placement means you can now walk in and test it rather than ordering blind. For anyone already in the Olive Young ecosystem, the Real Hyaluronic line is the one to watch — it's the product family that earned the Olive Young Award and is now carrying the brand's entire international expansion.